Innovation
Improved tissue forms & delivery options.
The HydraTek® Process
Leading the
Industry.
Not all amniotic & placental tissue allografts are created equal. The HydraTek® Process uses new revolutionary technology and sophisticated processing methods to capitalize so the full natural potential of the placenta can be harvested and utilized as a transplant like no other company, preserving function and integrity in their natural hydrated state while allowing for improved handling and delivery methods. The HydraTek® Process has proven quality, clinical adoption with over 250,000 implants to date - providing the utmost in patient safety and allograft preservation.
Quality
Preservation of tissue integrity & natural hydration.
Safety
Stringent donor screening, tissue testing, and safety standards.
Who we are.
Human Regenerative Technologies, LLC (HRT®) is a majority owned Skye Biologics Holdings Company focused since 2013 on advancing the development of human amniotic and placental properties through scientific understanding and advanced tissue allograft preservation, all under 361 of the PHS Act and 21 CFR Part 1271. Our allograft team has over 50 years of combined experience working in the 361 tissue allografts space. Our team’s research and development has enabled HRT® to emerge as a tissue bank leader in natural human tissue allografts derived from amniotic membranes and placental connective tissues. HRT® continues to advance tissue preservation technologies derived from the dynamic placental system, which provides the foundation of the body’s various tissues and organs.
